Vemurafenib + Rituximab for Hairy Cell Leukemia

"This scientific experiment is searching for twenty people with leukemia aged 18 to 90. To become eligible, individuals must pass a serum pregnancy test conducted within the week prior to receiving treatment (only applicable for women premenopausal). Additionally, participants have to sign an informed consent document and meet certain medical criteria such as having ECOG performance status of 0-2 ,acceptable organ function during screening not exacerbated by HCL and bilirubin ≤ 1.5 times upper limit of normal etc. Lastly, male patients with female partners are expected to use barrier contraception while all women of childbearing potential need acceptably effective contraceptive methods throughout the study's duration."

"According to clinicaltrials.gov, this medical experiment is currently searching for eligible patients with the trial having been posted on January 1st 2022 and most recently updated on May 19th of that same year."

"Our team at Power has rated the safety of Low dose vemurafenib plus rituximab as a 2. This is due to Phase 2 trial results, providing limited data regarding its efficacy and some information concerning its security."

"Affirmative. It is evident from the information hosted on clinicaltrials.gov that this medical trial first appeared online in January of 2022 and was last updated in May, with an aim to recruit 20 patients at a single site."

"To be eligible for this medical trial, patients must have attained the age of majority and not yet reached their ninetieth birthday. There are 427 trials available to those below 18 years old and 1,127 studies accessible to individuals over 65."